The field of medicine is continuously adopting new technologies, more so the surgical department. One technique that is rapidly gaining popularity is the minimally invasive surgical technique due to the small incision and fewer recovery days. With the demand for minimally invasive surgery, surgeons such as Dr. Ira Kirshenbaum are rapidly growing in need.
Dr. Ira Kirshenbaum is a specialist in minimally invasive knee and hip replacement. Trained in Rothman Institute, for years, Dr. Ira has been a member of the American Academy of Orthopedics. He is also a member of The American Association of hip and knees surgeons. In 1994, Dr. Ira received the James A. Vohs award, a prestigious award given to doctors who exhibit quality in their line of specialism. Dr. Ira has been at the forefront of designing new technologies which erase the burden carried by patients. He is most renowned for designing a cement-less hip system.
Minimal invasive surgeries involve the use of advanced robots, which allows doctors to have a 3d view for a particular part of interest. These robotic devices have been designed to give surgeons better vision while also allowing them to have more control when carrying out surgeries. Additionally, these devices come with robotic arms which replace traditional hand movements, hence giving surgeons precise locations. All of these benefits can be achieved with incisions between one to two inches long.
There are a host of benefits to a patient who has accepted this type of surgery. One significant benefit is the size of the incision. A traditional surgery required incisions of between four to six inches; but for minimally invasive surgery, incisions are quite smaller between one and two inches. This difference in incision allows patients to move easily after the surgery. Additionally, this technique is less painful and allows patients to heal faster. After surgery, less swelling is witnessed in the area and also less invasion of the most sensitive nerves. Ultimately, patients are not required to use stronger drugs to relieve pain.
Find out more here https://www.beckersasc.com/asc-turnarounds-ideas-to-improve-performance/dr-ira-kirschenbaum-undergoes-outpatient-total-knee-replacement-with-swiftpath-5-key-notes.html
With its headquarters situated in Cranbury, New Jersey, Amicus Therapeutics is among the leading biopharmaceutical companies in America. The company was officially launched in 2007 under the FOLD trading symbol of NASDAQ. The company has since flourished in the healthcare industry following that it registered an impressive increase in revenue by 71.4% in the second quarterly year from the previous first one (Crunchbase). Before its initial public opening, Amicus Therapeutics was initially the brainchild of several venture capital firms, including Canaan Partners and New Enterprise Associates, just to mention a few.
The Institute centers its focus on diseases that are collectively called lysosomal storage disorders. They also participate in the advancement of Chaperone-Advance Replacement and enzyme replacement therapies (http://www.marketwatch.com/investing/stock/fold). Initially, the company had no marketed products, but through their first partnerships with JCR Pharmaceutical and GlaxoSmithKline, they began with the development of migalastat monotherapy. Since the institute has no capacity to manufacture its products, it simply relies on contract manufacturing.
Amicus Therapeutics’ Chief Executive Officer has been John F. Crowley ever since 2005. Mr. Crowley preceded Donald Hayden, Jr. chairman of the company’s board while Hayden was reinstated in as the Lead Independent Director.
In the company’s bid to research on rare and orphan disorders, Amicus Therapeutics has received grants from the Foundation of Alzheimer’s Drug Discovery and the Michael J. Fox Foundation. These funds were especially allocated to the research and studies of rare diseases. The company was also successful in acquiring their competitor, Callidus Biopharma, in 2013, thereby obtaining all intellectual property on the advancement of enzyme replacement therapy for Pompe disease.
The company also formulated a belief statement that defines their core values and their level of commitment towards enhancing therapies for orphan diseases. In their belief statement, they state that they firmly believe in remaining at the forefront of advancement of therapies for rare and orphan diseases.